First patient included in OssDsign’s clinical study of the synthetic bone graft OssDsign Catalyst
Uppsala, 8 September 2021 - OssDsign AB (publ) today announced that the first patient has been included in the company’s clinical study TOP FUSION to investigate the long-term safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. The study will be conducted at the National Center for Spinal Disorders under the leadership of Dr Péter Pál Varga and Dr Áron Lazary.OssDsign Catalyst is a market cleared synthetic bone graft based on a patented nanocrystalline solution that stimulates the formation of healthy bone tissue. Data from a recently published pre-
